TP53 and chronic myelogenous leukemia, BCR-ABL1 positive: The inhibition of E2F1 in chronic myeloid leukemia (CML) stem/progenitor cells (SPCs) reduced proliferation of CML SPCs, leading to p53-mediated apoptosis.